Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Chouaid

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Revue Des Maladies Respiratoires|December 18, 2010
[Adult asthma exacerbations in questions]D Montani, A Cavailles, L Bertoletti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 2, 2014
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 studyJ B Auliac, C Chouaid, L Greillier, et al.
ESMO Real World Data and Digital Oncology|April 20, 2026
Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise studyS Lay-Flurrie, A Greystoke, C Rault, et al.
Annals of Hematology|June 10, 2023
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX studyM Macro, C Hulin, L Vincent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trialF Barlesi, A Scherpereel, V Gorbunova, et al.
Targeted Oncology|August 29, 2015
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 StudyJ B Auliac, C Fournier, C Audigier Valette, et al.
ESMO Open|June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohortQ D Thomas, X Quantin, P Lemercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trialM Schuler, J C-H Yang, K Park, et al.
ESMO Open|May 28, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trialM C Garassino, J Khalifa, M Reck, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Revue Des Maladies Respiratoires|December 18, 2010
[Adult asthma exacerbations in questions]D Montani, A Cavailles, L Bertoletti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 2, 2014
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 studyJ B Auliac, C Chouaid, L Greillier, et al.
ESMO Real World Data and Digital Oncology|April 20, 2026
Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise studyS Lay-Flurrie, A Greystoke, C Rault, et al.
Annals of Hematology|June 10, 2023
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX studyM Macro, C Hulin, L Vincent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trialF Barlesi, A Scherpereel, V Gorbunova, et al.
Targeted Oncology|August 29, 2015
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 StudyJ B Auliac, C Fournier, C Audigier Valette, et al.
ESMO Open|June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohortQ D Thomas, X Quantin, P Lemercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trialM Schuler, J C-H Yang, K Park, et al.
ESMO Open|May 28, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trialM C Garassino, J Khalifa, M Reck, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Pageof 12